<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bucayu RFT</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><funding>PEdiatric Antifungal Comparative Effectiveness</funding><funding>Centers for Disease Control and Prevention</funding><funding>Canada Research Chair in Pediatric Oncology Supportive Care</funding><funding>NIDDK NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>Cystic Fibrosis Foundation</funding><funding>AHRQ</funding><funding>National Institutes of Health, Food Drug and Aministration</funding><funding>National Institute of Diabetes, Digestive, and Kidney Diseases</funding><funding>National Institutes of Health</funding><pagination>633-638</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12476979</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(12)</volume><pubmed_abstract>Of 319 children with invasive candidiasis, 67 (21%) transitioned from intravenous to enteral antifungal therapy. Eight (12%) transitioned back to intravenous antifungal therapy, one due to perceived treatment failure defined by clinical progression or worsening. Global treatment response at study completion was successful in 66 participants who transitioned to enteral therapy.</pubmed_abstract><journal>Journal of the Pediatric Infectious Diseases Society</journal><pubmed_title>Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network.</pubmed_title><pmcid>PMC12476979</pmcid><funding_grant_id>1K12DK111028</funding_grant_id><funding_grant_id>K12 DK111028</funding_grant_id><funding_grant_id>R01 AI103315</funding_grant_id><funding_grant_id>5R01AI103315</funding_grant_id><pubmed_authors>Wattier RL</pubmed_authors><pubmed_authors>Aftandilian C</pubmed_authors><pubmed_authors>Maron G</pubmed_authors><pubmed_authors>Arrieta AC</pubmed_authors><pubmed_authors>Lutsar I</pubmed_authors><pubmed_authors>Belani K</pubmed_authors><pubmed_authors>Danziger-Isakov L</pubmed_authors><pubmed_authors>Chakrabarti A</pubmed_authors><pubmed_authors>Johnson SK</pubmed_authors><pubmed_authors>Vora SB</pubmed_authors><pubmed_authors>Rajan S</pubmed_authors><pubmed_authors>Fisher BT</pubmed_authors><pubmed_authors>Tribble AC</pubmed_authors><pubmed_authors>Dulek D</pubmed_authors><pubmed_authors>Palazzi DL</pubmed_authors><pubmed_authors>Steinbach WJ</pubmed_authors><pubmed_authors>Salvatore CM</pubmed_authors><pubmed_authors>Knackstedt ED</pubmed_authors><pubmed_authors>Sung L</pubmed_authors><pubmed_authors>Roilides E</pubmed_authors><pubmed_authors>Halasa N</pubmed_authors><pubmed_authors>Nolt D</pubmed_authors><pubmed_authors>Ardura MI</pubmed_authors><pubmed_authors>Gonzalez BE</pubmed_authors><pubmed_authors>Romero J</pubmed_authors><pubmed_authors>Soler-Palacin P</pubmed_authors><pubmed_authors>Pong A</pubmed_authors><pubmed_authors>Bucayu RFT</pubmed_authors><pubmed_authors>Abzug MJ</pubmed_authors><pubmed_authors>Boge CLK</pubmed_authors><pubmed_authors>Carlesse F</pubmed_authors><pubmed_authors>Muller WJ</pubmed_authors><pubmed_authors>Lopez-Medina E</pubmed_authors><pubmed_authors>Green M</pubmed_authors><pubmed_authors>Yildirim I</pubmed_authors><pubmed_authors>Berman DM</pubmed_authors><pubmed_authors>Aviles-Robles M</pubmed_authors><pubmed_authors>Yin DE</pubmed_authors><pubmed_authors>Castagnola E</pubmed_authors><pubmed_authors>Sharma TS</pubmed_authors><pubmed_authors>Huppler AR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network.</name><description>Of 319 children with invasive candidiasis, 67 (21%) transitioned from intravenous to enteral antifungal therapy. Eight (12%) transitioned back to intravenous antifungal therapy, one due to perceived treatment failure defined by clinical progression or worsening. Global treatment response at study completion was successful in 66 participants who transitioned to enteral therapy.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2026-06-03T23:22:36.379Z</modification><creation>2026-05-03T03:11:12.907Z</creation></dates><accession>S-EPMC12476979</accession><cross_references><pubmed>39513400</pubmed><doi>10.1093/jpids/piae116</doi></cross_references></HashMap>